

SUPPLEMENTARY PROSPECTUS DATED 30 AUGUST 2019

LLOYDS BANK
CORPORATE MARKETS



LLOYDS BANK CORPORATE MARKETS plc

(incorporated in England with limited liability with registered number 10399850)

£10,000,000,000

Euro Medium Term Note Programme

This Supplement (the “**Supplement**”) to the prospectus dated 25 June 2019 (the “**Prospectus**”), which comprises a base prospectus for the purposes of Article 5.4 of Directive 2003/71/EC, constitutes a supplementary prospectus for the purposes of Directive 2003/71/EC and Section 87G of the Financial Services and Markets Act 2000, as that provision stood immediately prior to 21 July 2019, and is prepared in connection with the £10,000,000,000 Euro Medium Term Note Programme (the “**Programme**”) established by Lloyds Bank Corporate Markets plc (the “**Issuer**”).

This Supplement is supplemental to, and should be read in conjunction with, the Prospectus and the documents incorporated by reference therein. Capitalised terms used in this Supplement but not defined herein shall have the meanings ascribed to them in the Prospectus.

The Issuer accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Issuer (having taken all reasonable care to ensure that such is the case) the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Purpose of this Supplement

The purpose of this Supplement is to:

- (a) incorporate by reference into the Prospectus the 2019 Half-Year Results (as defined in this Supplement), which were published via the RNS on 30 August 2019; and
- (b) update the no significant change statement of the Issuer and its subsidiary and associated undertakings (the “**LBCM Group**”).

(a) Documents Incorporated by Reference

By virtue of this Supplement, the Issuer’s 2019 Half-Year Results for the half-year to 30 June 2019, including the unaudited condensed consolidated financial statements prepared on a statutory basis for the half-year to 30 June 2019, together with the independent review report thereon, as set out on pages 34 to 35 thereof, respectively (the “**2019 Half-Year Results**”), which have previously been published and filed with the Financial Conduct Authority, shall be deemed to be incorporated in, and form part of, the Prospectus and supplement the section entitled “*Documents Incorporated by Reference*” on page 9 of the Prospectus.

Any documents themselves incorporated by reference in the 2019 Half-Year Results shall not form part of the Prospectus.

(b) No significant change of the LBCM Group and no material adverse change of the Issuer

The no significant change of the LBCM Group and no material adverse change of the Issuer statement at paragraph 2 on page 137 of the Prospectus is updated as stated below:

There has been no significant change in the financial position of the LBCM Group since 30 June 2019, the date to which the LBCM Group's last published unaudited interim financial information (as set out in the Issuer's 2019 Half-Year Results) was prepared. There has been no material adverse change in the prospects of the Issuer since 31 December 2018, the date to which the Issuer's last published audited financial information (as set out in the Issuer's 2018 Annual Report) was prepared.

The Issuer will provide, without charge, to each person to whom a copy of this Supplement has been delivered, upon the oral or written request of such person, a copy of any or all of the documents which are incorporated in whole or in part by reference herein or in the Prospectus. Written or oral requests for such documents should be directed to the Issuer at its principal office at 25 Gresham Street, London, EC2V 7HN. Copies of all documents incorporated by reference in this Supplement can also be viewed on the website of the Regulatory News Service operated by the London Stock Exchange at: <https://www.londonstockexchange.com/exchange/news/market-news/market-news-home.html>.

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Prospectus by this Supplement and (b) any other statement in or incorporated by reference into the Prospectus, the statements in (a) above will prevail.

Save as disclosed in this Supplement, no other significant new factor, material mistake or inaccuracy relating to information included in the Prospectus has arisen or been noted, as the case may be, since the publication of the Prospectus.